Literature DB >> 11164842

Enhancement of Rho/Rho-kinase system in regulation of vascular smooth muscle contraction in tachycardia-induced heart failure.

T Hisaoka1, M Yano, T Ohkusa, M Suetsugu, K Ono, M Kohno, J Yamada, S Kobayashi, M Kohno, M Matsuzaki.   

Abstract

OBJECTIVE: The Rho/Rho-kinase system regulates Ca(2+) sensitivity in vascular smooth muscle. A new drug, Y-27632, specifically inhibits Rho-kinase and hence decreases the phosphorylation of myosin light chain, thus reducing contraction. Here, we compare the effects of Y-27632 and nifedipine on the vasoconstrictor response of the femoral artery in heart failure.
METHODS: Heart failure (HF) was produced by chronic rapid RV pacing (250 bpm, 28 days, six dogs). Indo1-AM was loaded into endothelium-denuded femoral artery segments for measuring intracellular [Ca(2+)]. Tension and changes in intracellular [Ca(2+)] [the change in the ratio (418 nm/468 nm) of Indo1 fluorescence (F(ratio))] were simultaneously measured in Krebs-Ringer solution.
RESULTS: In HF: (i) norepinephrine (10 microM) produced greater tension (784+/-52 g/cm(2)) than in control (502+/-64 g/cm(2)) despite a similar increase in F(ratio), indicating increased Ca(2+) sensitivity in vascular smooth muscle; (ii) nifedipine attenuated this enhanced response by only a maximum of 27% at 1 micromol/l with a 56% reduction in F(ratio); (iii) Y-27632 attenuated it by a maximum of 80% at 100 micromol/l without a significant change in F(ratio); (iv) RhoA protein and mRNA expression levels in the femoral artery were up-regulated by +110% and +56%, respectively, while those of Rho-kinase were unchanged.
CONCLUSIONS: The Ca(2+)-sensitizing mechanism involving the Rho/Rho-kinase system may be deeply involved in the enhanced arterial vasoconstriction seen in HF. Since Y-27632 attenuated this response in small arteries, it shows potential as a novel, potent vasodilator for the treatment of HF.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11164842     DOI: 10.1016/s0008-6363(00)00279-0

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  7 in total

Review 1.  The Search for Disease-Modifying Therapies in Pulmonary Hypertension.

Authors:  Chen-Shan Chen Woodcock; Stephen Y Chan
Journal:  J Cardiovasc Pharmacol Ther       Date:  2019-02-17       Impact factor: 2.457

2.  Interference of Y-27632 on the signal transduction of transforming growth factor beta type 1 in ocular Tenon capsule fibroblasts.

Authors:  Xiao-Hui Zhang; Nai-Xue Sun; Zhao-Hui Feng; Chao Wang; Yi Zhang; Jian-Ming Wang
Journal:  Int J Ophthalmol       Date:  2012-10-18       Impact factor: 1.779

Review 3.  Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases.

Authors:  Ming Dong; Bryan P Yan; James K Liao; Yat-Yin Lam; Gabriel W K Yip; Cheuk-Man Yu
Journal:  Drug Discov Today       Date:  2010-06-25       Impact factor: 7.851

4.  Increased Rho kinase activity in congestive heart failure.

Authors:  Ming Dong; James K Liao; Fang Fang; Alex Pui-Wai Lee; Bryan Ping-Yen Yan; Ming Liu; Cheuk-Man Yu
Journal:  Eur J Heart Fail       Date:  2012-05-15       Impact factor: 15.534

5.  Involvement of RhoA-mediated Ca2+ sensitization in antigen-induced bronchial smooth muscle hyperresponsiveness in mice.

Authors:  Yoshihiko Chiba; Ayako Ueno; Koji Shinozaki; Hisao Takeyama; Shuji Nakazawa; Hiroyasu Sakai; Miwa Misawa
Journal:  Respir Res       Date:  2005-01-08

6.  Drug target identification using network analysis: Taking active components in Sini decoction as an example.

Authors:  Si Chen; Hailong Jiang; Yan Cao; Yun Wang; Ziheng Hu; Zhenyu Zhu; Yifeng Chai
Journal:  Sci Rep       Date:  2016-04-20       Impact factor: 4.379

7.  Corneal Endothelial Cell Migration and Proliferation Enhanced by Rho Kinase (ROCK) Inhibitors in In Vitro and In Vivo Models.

Authors:  Landon C Meekins; Noel Rosado-Adames; Rupalatha Maddala; Jiagang J Zhao; Ponugoti V Rao; Natalie A Afshari
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-12-01       Impact factor: 4.799

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.